Psyence BioMed Expands Australian Network to Five Sites for Phase IIb NPX-5 Trial
Psyence BioMed has expanded its Australian clinical network from three to five sites by adding Ramsay Health Care and NeuroCentrix to support its Phase IIb NPX-5 psilocybin trial in palliative oncology patients. The expansion is expected to accelerate patient recruitment, enrollment and operational efficiency across multi-site study locations.
1. Expansion of Australian Site Network
Psyence BioMed has added Ramsay Health Care and NeuroCentrix to its Australian clinical network, increasing active sites from three to five. This expansion supports the Phase IIb natural psilocybin trial in palliative oncology, aiming to strengthen recruitment and accelerate patient enrollment across multiple locations.
2. NPX-5 Supply and Trial Advancement
The company is supplying GMP-compliant NPX-5 capsules in 1mg and 5mg strengths from its PsyLabs facility, underpinning ongoing clinical activities. The expanded network is expected to improve operational efficiency and generate robust data for Adjustment Disorder treatment in cancer patients under palliative care.